Research programme: EP4 receptor antagonists - Rottapharm

Drug Profile

Research programme: EP4 receptor antagonists - Rottapharm

Alternative Names: CR5790

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Rottapharm Madaus
  • Class Small molecules
  • Mechanism of Action Prostaglandin E EP4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Osteoarthritis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Osteoarthritis in Italy
  • 10 Oct 2014 Rottapharm Madaus has been acquired by Meda
  • 24 Feb 2010 Early research in Osteoarthritis in Italy (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top